Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous...

cafead

Administrator
Staff member
  • cafead   Jan 15, 2021 at 09:52: AM
via Novartis has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for its ligelizumab (QGE031) to treat chronic spontaneous urticarial.

article source